Key result
BI 456906 reduced placebo-corrected bodyweight by up to 12.37% after 16 weeks of treatment in healthy Japanese men with overweight/obesity.
Why the study?
Does BI 456906 reduce bodyweight and demonstrate safety in healthy Japanese men with overweight/obesity?
Comparison
Subcutaneous BI 456906 vs placebo
Design
Randomized Phase I study
Follow-up
16 weeks
Authors
Loading...
May support weight management with BI 456906 in overweight Japanese men; extends RCT evidence to this population.
RCT (n=36)
Does BI 456906 reduce bodyweight and demonstrate safety in healthy Japanese men with overweight/obesity?
Absolute Event Rate: -12.37% vs 1.06%
The dual GCGR/GLP-1R agonist BI 456906 demonstrated substantial weight loss and expected tolerability profiles in a Phase I study of Japanese men with overweight/obesity.
Yazawa et al. (2023) conducted an RCT in overweight/obesity (n=36). BI 456906 vs. placebo was evaluated on placebo-corrected bodyweight change. BI 456906 reduced placebo-corrected bodyweight by up to 12.37% after 16 weeks of treatment in healthy Japanese men with overweight/obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: